Stratec SE (STSEY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Stratec SE (STSEY) trades at $5.51 with AI Score 42/100 (Grade C). Stratec SE designs and manufactures automation and instrumentation solutions for in-vitro diagnostics and life sciences. Market cap: $1.67B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for STSEY: STSEY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates STSEY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
STSEY: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Stratec SE (STSEY) Healthcare & Pipeline Overview
Stratec SE, founded in 1979, specializes in automation and instrumentation for in-vitro diagnostics and life sciences. Operating globally with a focus on its Instrumentation, Diatron, and Smart Consumables segments, the company provides solutions to clinical diagnostics and biotechnology customers, boasting a market capitalization of $1.67B and a P/E ratio of 14.63.
What Is the Investment Thesis for STSEY?
Stratec SE presents a compelling investment case based on its established position in the in-vitro diagnostics and life sciences automation market. With a market capitalization of $1.67B and a P/E ratio of 14.63, the company demonstrates financial stability. Key value drivers include the increasing demand for automated diagnostic solutions, particularly in emerging markets, and the expansion of its Smart Consumables segment. The company's 6.1% profit margin and 29.1% gross margin indicate efficient operations. Ongoing catalysts include strategic partnerships and product innovation. Potential risks include regulatory changes and competition from established players. Stratec's beta of 0.72 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
STSEY Key Highlights
Market capitalization of $1.67B reflects Stratec's significant presence in the medical devices industry.
- P/E ratio of 14.63 indicates a potentially undervalued stock compared to industry peers.
- Profit margin of 6.1% demonstrates the company's ability to generate profit from its revenue.
- Gross margin of 29.1% showcases efficient cost management in the production of its automation and instrumentation solutions.
- Dividend yield of 3.18% provides an attractive return for investors seeking income.
Who Are STSEY's Competitors?
STSEY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARSUF Fagron N.V. | $27.50 | +0.00% | $2.02B | 54 |
| DRWKF Drägerwerk AG & Co. KGaA | $100.47 | +0.00% | $1.88B | 50 |
| EBOSY EBOS Group Limited | $26.00 | +0.00% | $1.33B | 42 |
| IUSDF AS ONE Corporation | $14.00 | +0.00% | $998M | 46 |
| MEDGF Medacta Group S.A. | $160.00 | +0.00% | $3.19B | 55 |
| INSP Inspire Medical Systems, Inc. | $61.27 | -0.68% | $1.77B | 97 |
| FDMDF 4DMedical Limited | $2.95 | -7.81% | $1.77B | 61 |
| CNMD CONMED Corporation | $51.38 | +0.25% | $1.54B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are STSEY's Key Strengths?
Strong market position in in-vitro diagnostics automation.
- Diversified product portfolio across Instrumentation, Diatron, and Smart Consumables segments.
- Global presence with established distribution networks.
- Experienced management team with a focus on innovation.
What Are STSEY's Weaknesses?
Dependence on key customers and suppliers.
- Exposure to regulatory changes in the healthcare industry.
- Limited brand recognition compared to larger competitors.
- Potential for product recalls or liability claims.
What Could Drive STSEY Stock Higher?
Expansion of the Smart Consumables segment, driving recurring revenue and higher margins.
- Strategic partnerships with pharmaceutical companies to develop personalized medicine solutions.
- Launch of new automated analyzer systems for clinical diagnostics in Q4 2026.
- Increasing demand for in-vitro diagnostics in emerging markets.
- Continued investment in research and development to drive product innovation.
What Are the Key Risks for STSEY?
Negative return on equity (-1.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory changes in the healthcare industry could impact product approvals and reimbursement rates.
- Intense competition from established players in the medical devices industry.
- Economic downturns could reduce healthcare spending and demand for diagnostic solutions.
- Currency risk due to international operations and fluctuations in exchange rates.
- Product recalls or liability claims could damage the company's reputation and financial performance.
What Are the Growth Opportunities for STSEY?
- Expansion in Emerging Markets: Stratec has the opportunity to expand its presence in emerging markets, where healthcare infrastructure is developing and the demand for advanced diagnostic solutions is increasing. These markets offer significant growth potential due to their large populations and rising healthcare expenditure. Timeline: Ongoing, with a focus on strategic partnerships and distribution agreements to penetrate these markets effectively. Market Size: The emerging markets in Asia-Pacific and Latin America represent a multi-billion dollar opportunity for in-vitro diagnostics.
- Strategic Partnerships and Acquisitions: Stratec can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with or acquiring companies with complementary technologies or geographical presence can accelerate growth and enhance competitiveness. Timeline: Ongoing, with a focus on identifying and integrating synergistic businesses. Market Size: The market for mergers and acquisitions in the medical devices industry is substantial, with deal values reaching billions of dollars annually.
- Product Innovation and Development: Stratec can invest in research and development to introduce innovative products and solutions that address unmet needs in the in-vitro diagnostics and life sciences markets. Developing new assays, instruments, and consumables can drive revenue growth and strengthen its competitive position. Timeline: Ongoing, with a focus on leveraging technological advancements and customer feedback. Market Size: The global market for new diagnostic technologies is estimated to be worth billions of dollars.
- Focus on Personalized Medicine: Stratec can capitalize on the growing trend of personalized medicine by developing diagnostic solutions that enable tailored treatment approaches. This involves developing assays and instruments that can analyze individual patient samples and provide insights for personalized therapy decisions. Timeline: Ongoing, with a focus on collaborating with pharmaceutical companies and research institutions.
- Increased Focus on Smart Consumables: Stratec's Smart Consumables segment presents a significant growth opportunity. By developing and manufacturing advanced consumables for diagnostics, life sciences, and medical technologies, Stratec can generate recurring revenue streams and enhance customer loyalty. Timeline: Ongoing, with a focus on expanding the product portfolio and optimizing manufacturing processes. Market Size: The global market for medical consumables is estimated to be worth billions of dollars.
What Are STSEY's Competitive Advantages?
- Proprietary technology in automation and instrumentation solutions.
- Established relationships with clinical diagnostics and biotechnology customers.
- Strong brand reputation for quality and reliability.
- Recurring revenue from consumables and service contracts.
What Does STSEY Do?
Stratec SE, established in 1979 and headquartered in Birkenfeld, Germany, operates as a key player in the healthcare sector, specifically within the medical devices industry. The company designs and manufactures automation and instrumentation solutions for in-vitro diagnostics and life sciences. Stratec serves a global clientele, with a significant presence in Germany, the European Union, and other international markets. Its operations are structured into three primary segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment is responsible for the design and manufacture of automated analyzer systems, including service parts and consumables, catering to clinical diagnostics and biotechnology customers. The Diatron segment focuses on providing systems, system components, consumables, and tests for low-throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures specialized consumables for diagnostics, life sciences, and medical technologies. Originally named STRATEC Biomedical AG, the company rebranded as Stratec SE in December 2018. Stratec's evolution reflects its commitment to innovation and its strategic focus on expanding its product portfolio and market reach within the in-vitro diagnostics and life sciences sectors. The company's solutions are integral to laboratories and healthcare providers, enabling efficient and accurate diagnostic testing.
What Products and Services Does STSEY Offer?
- Designs and manufactures automated analyzer systems for clinical diagnostics.
- Provides instrumentation solutions for the life sciences industry.
- Offers systems and components for low-throughput hematology applications.
- Develops and manufactures smart consumables for diagnostics.
- Creates solutions for clinical chemistry applications.
- Provides service parts and consumables for its instrumentation systems.
- Offers tests for hematology and clinical chemistry applications.
How Does STSEY Make Money?
- Sells automated analyzer systems to clinical diagnostics and biotechnology customers.
- Generates revenue from the sale of service parts and consumables for its systems.
- Offers systems and components for low-throughput hematology and clinical chemistry applications.
- Develops and manufactures smart consumables for diagnostics, life sciences, and medical technologies.
What Industry Does STSEY Operate In?
Stratec SE operates within the medical devices industry, a sector characterized by continuous innovation and increasing demand for advanced diagnostic solutions. The global in-vitro diagnostics market is projected to grow, driven by factors such as an aging population, the rising prevalence of chronic diseases, and technological advancements. Stratec competes with companies like ARSUF, DRWKF, EBOSY, IUSDF, and MEDGF, all vying for market share in this expanding landscape. Stratec's focus on automation and instrumentation positions it to capitalize on the trend toward laboratory efficiency and accuracy.
Who Are STSEY's Key Customers?
- Clinical diagnostic laboratories
- Biotechnology companies
- Hospitals and healthcare providers
- Research institutions
- Pharmaceutical companies
Company Profile
Stratec SE operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Birkenfeld, DE. The company is led by CEO Marcus Wolfinger. STSEY has traded publicly since 2020.
Stratec SE Financial Trajectory
Stratec SE (STSEY) reported $60.1M in revenue for Q2 2026, reflecting 12.5% growth compared to the prior quarter. The company recorded net income of $4.2M, with diluted EPS of $0.01. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, STSEY averaged $-0.00 in diluted EPS.
How Stratec SE Is Valued
Stratec SE carries a market capitalization of $1.67B, placing it in the small-cap category. Relative to its peer group, STSEY's quantitative score of 42/100 is roughly in line with the peer average of 49/100.
Key Financial Metrics
Return on equity for Stratec SE stands at -1.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.8%, showing how much profit it generates from its asset base. Its free cash flow yield is 5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.33 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Stratec SE's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 6.10 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project Stratec SE revenue of about $265.2M for fiscal 2026, with EPS near $0.00.
STSEY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in Stratec's growth potential, suggesting management believes in the company's future.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments that could drive revenue.
- Analysts are noting increased demand for Stratec's diagnostic solutions, aligning with broader healthcare trends.
- Market perception is buoyed by strategic partnerships that enhance Stratec's market reach and operational capabilities.
Bear Case
- Concerns have been raised about supply chain disruptions affecting Stratec's production timelines, leading to uncertainty in delivery schedules.
- Some community members express skepticism about the sustainability of recent growth, fearing it may not be long-term.
- Recent regulatory changes in the healthcare sector could pose challenges to Stratec's operations and profitability.
- Market sentiment remains cautious, with discussions around potential competition intensifying, which could impact Stratec's market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $60M | $4M | $0.01 |
| Q1 2026 | $53M | -$2M | -$0.01 |
| Q4 2025 | $75M | -$4M | -$0.01 |
| Q3 2025 | $57M | $2M | $0.01 |
Based on FMP financials and quantitative analysis
STSEY Latest News
No recent news available for STSEY.
STSEY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for STSEY.
Price Targets
Wall Street price target analysis for STSEY.
STSEY MoonshotScore
What does this score mean?
The MoonshotScore rates STSEY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Marcus Wolfinger
CEO
Marcus Wolfinger serves as the CEO of Stratec SE, leading a workforce of 1462 employees. His background includes extensive experience in the healthcare and technology sectors. Before joining Stratec, he held various leadership positions in multinational corporations, focusing on strategic planning, business development, and operational excellence. He holds an advanced degree in engineering and a business administration degree.
Track Record: Under Marcus Wolfinger's leadership, Stratec SE has focused on expanding its global presence and strengthening its product portfolio. Key achievements include strategic acquisitions and partnerships that have enhanced the company's competitive position. He has also overseen the implementation of operational efficiencies and the development of innovative diagnostic solutions.
Stratec SE ADR Information Unsponsored
An American Depositary Receipt (ADR) like STSEY represents shares of a foreign company (Stratec SE) trading on U.S. exchanges. It allows U.S. investors to invest in Stratec without dealing with foreign exchanges. STSEY is an unsponsored Level 1 ADR, meaning Stratec has limited involvement in its creation and trading.
- Home Market Ticker: Primary stock exchange: Frankfurt Stock Exchange (Xetra) in Germany.
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: STSE
STSEY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Stratec SE (STSEY) may have limited regulatory oversight and reporting requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier often have minimal financial disclosure, which increases investment risk due to lack of transparency.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Lower liquidity can make it difficult to buy or sell shares without impacting the price.
- Potential for price manipulation due to less regulatory oversight.
- Higher volatility compared to stocks listed on major exchanges.
- Risk of delisting or suspension from the OTC market.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements and reports.
- Assess the company's management team and their track record.
- Research the company's industry and competitive landscape.
- Understand the company's business model and revenue streams.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a financial advisor or legal professional.
- Established operating history in the in-vitro diagnostics and life sciences sectors.
- Presence in Germany, European Union, and international markets.
- Audited financial statements (if available).
- Positive news coverage and industry recognition.
- Partnerships with reputable organizations.
Common Questions About STSEY (Healthcare)
What does the AI Score mean for STSEY?
STSEY holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Stratec SE designs and manufactures automation and instrumentation solutions for in-vitro diagnostics and life sciences. The company operates through three segments: Instrumentation, Diatron, …
What does Stratec SE do?
Stratec SE specializes in designing and manufacturing automation and instrumentation solutions for the in-vitro diagnostics and life sciences sectors. The company operates through three segments: Instrumentation, Diatron, and Smart Consumables. Its products include automated analyzer systems, system components for hematology and clinical chemistry, and smart consumables for diagnostics and medical technologies. Stratec serves clinical diagnostic laboratories, biotechnology companies, and healthcare providers globally, enabling efficient and accurate diagnostic testing.
What do analysts say about STSEY stock?
Analyst coverage of Stratec SE (STSEY) is limited due to its OTC listing and ADR Level 1 status. However, key valuation metrics such as its P/E ratio of 14.63 and dividend yield of 3.18% provide some insight into its financial health. Growth considerations include the expansion of its Smart Consumables segment and strategic partnerships in personalized medicine.
What are the main risks for STSEY?
The main risks for Stratec SE include regulatory changes in the healthcare industry, intense competition from established players, economic downturns that could reduce healthcare spending, currency risk due to international operations, and potential product recalls or liability claims. Additionally, as an OTC-listed stock, STSEY faces risks related to limited financial disclosure, lower liquidity, and potential price manipulation.
What are the key factors to evaluate for STSEY?
Stratec SE (STSEY) holds an AI score of 42/100 (low). Stratec SE presents a compelling investment case based on its established position in the in-vitro diagnostics and life sciences automation market. Not financial advice.
How frequently does STSEY data refresh on this page?
STSEY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven STSEY's recent stock price performance?
Stratec SE (STSEY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in in-vitro diagnostics automation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider STSEY overvalued or undervalued right now?
Stratec SE (STSEY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research STSEY before investing?
Before investing in Stratec SE (STSEY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.